FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and deals with application of antibody to HER2 and/or antibody to VEGF for preparation of medication intended for reduction of metastases in treatment of breast cancer, characterised by super-expression of HER2 receptor protein in patient, unsusceptible to preceding therapy with application of antibody to VEGF, in which treatment includes introduction to patient of therapeutically effective amount of antibody to HER2 and antibody to VEGF, with antibody to VEGF representing bevacizumab, and antibody to HER2 representing trastuzumab. Group of inventions also deals with application of antibody to HER2 for reduction of metastases in method of breast cancer treatment and application of antibodies to VEGF for reduction of methastases in method of breast cancer treatment.
EFFECT: combination of bevacizumab and trastuzumab makes it possible to achieve prevention of metastases formation.
12 cl, 1 ex, 2 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING TUMOURS WITH VEGF ANTIBODY | 2007 |
|
RU2528884C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2510272C2 |
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS | 2018 |
|
RU2781195C2 |
| COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE | 2013 |
|
RU2671489C2 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
| MULTI-SPECIFIC ANTIBODIES INTENDED FOR USE IN TREATMENT OF URINARY TRACT NEOPLASM | 2017 |
|
RU2766358C2 |
| ANTI-ANGIOGENESIS THERAPY USED FOR TREATING BREAST CANCER | 2009 |
|
RU2531948C2 |
| CANCER-MODIFYING ANTIBODIES | 2008 |
|
RU2468036C2 |
